NCT07498439

TILs Therapy for Multiple Primary Early-Stage NSCLC

Safety Study of Tumor-Infiltrating Lymphocytes (TILs) Therapy for Multifocal Early-Stage Non-Small Cell Lung Cancer (NSCLC)

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Tianjin Medical University General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm study aimed at evaluating the safety of TILs therapy for multiple primary early-stage NSCLC

Detailed description

This study is an open-label, single-arm, prospective clinical trial. 50 subjects with multiple primary early-stage non-small cell lung cancer (NSCLC), including those with malignant pleural effusion, will be enrolled and administered with tumor-infiltrating lymphocytes (TILs) injection therapy. Adverse reactions, therapeutic efficacy and other relevant indicators will be closely observed and followed up, so as to systematically evaluate the safety and effectiveness of TILs treatment for multiple

Conditions

• Primary Early-stage Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	TILs injection	Experimental: Surgically collect fresh tumor tissue or malignant pleural effusion to isolate immune cells, and prepare TILs Infusion. Trial product: TILs Injection. Administration route: Intravenous Infusion

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-03-31
• Completion: 2030-03-31
• First posted: 2026-03-27
• Last updated: 2026-03-27